NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




NCI Community Oncology Research Program - Protocol Summary

SWOG S1417CD - "Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer"

The summary below serves as a brief review of the treatment plan and eligibility for the protocol.


This summary is not intended to be used in place of the full eligibility & treatment information in the protocol.
 

Please follow the "Full Protocol" link or contact KCCOP for complete protocol information.



Print This Summary

CCDR Clinical Trial

CANCER TYPE: GI
RESEARCH BASE: SWOG
NCT NUMBER: NCT02728804
HIPPA FORM: DOWNLOAD HIPPA FORM

Consent Form: VIEW CONSENT FORM
Additional Consent Form: VIEW CONSENT FORM 2

BRIEF DESCRIPTION

CCDR, patient questionnaires that assess the financial impact of metastatic colorectal ca.  DCP-001 Eligible



NOTES


THIS TRIAL IS DCP-001 ELIGIBLE

Questionnaires will be administered to patients at baseline, 3, 6, 9, and 12 months.  They are available on the SWOG website or you can contact NCORP-KC.

Caregiver participation is optional; however, the caregiver must provide separate written informed consent if they choose to participate.

 



ELIGIBILITY

  • Patients must have newly diagnosed metastatic colon or rectal cancer (mCRC) (de novo metastatic diagnosis) or metastatic recurrence after prior treatment for Stage I-III disease and be within 90 days after diagnosis at time of registration.
  • Systemic chemotherapy and/or systemic biologic therapy must be planned to be administered within 30 days after registration. Patients who have already started treatment or who are planning palliative or hospice care only (no chemotherapy or biologic therapy) are not eligible.
  • Patients must be at least 18 years of age.
  • Patients may not be enrolled (or planning enrollment) in a clinical treatment trial at the time of registration.
  • No prior malignancy other than CRC is allowed except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free for five years.
  • Patients must plan to receive treatment at the registering site. Registering site must be an NCORP CCDR site.
  • Patients must be able to complete questionnaires in English.
  • Patients must provide their full name, primary address in the U.S., birth date and social security number at registration for the purposes of accessing credit report data.
  • Patients must sign and give written informed consent in accordance with institutional and federal guidelines.





  © 2013-2018 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA